Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

111.98 -0.38 (-0.34%)
Official Closing Price Updated: 7:00 PM EDT, Oct 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,243,382
Open 111.62
Bid (Size) 112.25 (1)
Ask (Size) 112.64 (2)
Prev. Close 112.36
Today's Range 111.15 - 113.27
52wk Range 94.73 - 148.15
Shares Outstanding N/A
Dividend Yield 1.58%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Market Whales and Their Recent Bets on NVO Options
Via Benzinga
1 Huge New Reason to Buy Eli Lilly or Novo Nordisk Stock Right Now and Hold It Forever
One key disease-prevention market is drawing closer to being within reach. 
Via The Motley Fool

Performance

YTD
+9.67%
+9.67%
1 Month
-5.95%
-5.95%
3 Month
-13.35%
-13.35%
6 Month
-12.73%
-12.73%
1 Year
+16.16%
+16.16%

More News

Read More
Neuralink's Promise For Alzheimer's Has A Crucial Time Window — Elon Musk Explains Why
Via Benzinga
Smitten With Novo Nordisk
Via Talk Markets
This Is Huge News for Novo Nordisk (Hint: It Doesn't Involve Ozempic)
Via The Motley Fool
Benzinga Bulls And Bears: Nvidia, Tesla, MicroStrategy, Plug Power — And Crypto Traders Anticipate Dogecoin Topping 50 Cents
Via Benzinga
Behind the Scenes of Novo Nordisk's Latest Options Trends
Via Benzinga
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
Via Benzinga
Ozempic Can Potentially Cut Risk Of Alzheimer's Compared To Other Diabetic Medicines, Study Shows
Via Benzinga
Exposures Product Safety
Hims & Hers Stock Dropped: Here's What You Need to Know
Via The Motley Fool
Monster and Celsius Energized: Which Stock Offers More Upside?
Via MarketBeat
Topics ETFs
Ozempic And Wegovy Maker Novo Nordisk Asks FDA To Halt Production Of Compounded Fat Loss Drugs Due To Their 'Inherent Complexity'
Via Benzinga
Exposures Product Safety
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
Via Benzinga
Novo Nordisk's Death Cross: Is A Turnaround Coming For The Ozempic, Wegovy Maker?
Via Benzinga
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
Via Chartmill
Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?
Via Benzinga
Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises
Via Investor's Business Daily
Can Roche Challenge Lilly and Novo in the Weight Loss Market?
Via MarketBeat
Wegovy Maker Novo Nordisk's Oral Diabetes Pill Cuts Heart Attacks, Stroke Events By 14%
Via Benzinga
After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent
Via Benzinga
Europe Drug Regulator's Advising Panel Recommends Approval Of Novo Nordisk's Australia-Approved Hemophilia Drug
Via Benzinga
Novo Nordisk's Weight Loss Drug Ozempic Associated With Reduced Opioid, Alcohol Use Disorder Incidences, Study Shows
Via Benzinga
'Miracle' Weight Loss Drug Ozempic And Similar Drugs Reduce Alcohol And Opioid Overdose, Study Reveals
Via Benzinga
Hims & Hers Shares Have Rallied 22% This Week. Why That Move Is Now At Risk.
Via Investor's Business Daily
Exposures Product Safety
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.